JP2017517520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017517520A5 JP2017517520A5 JP2016569847A JP2016569847A JP2017517520A5 JP 2017517520 A5 JP2017517520 A5 JP 2017517520A5 JP 2016569847 A JP2016569847 A JP 2016569847A JP 2016569847 A JP2016569847 A JP 2016569847A JP 2017517520 A5 JP2017517520 A5 JP 2017517520A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- patient
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 101150080074 TP53 gene Proteins 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 12
- 108700025694 p53 Genes Proteins 0.000 claims 12
- 206010064571 Gene mutation Diseases 0.000 claims 9
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 claims 8
- 102100023037 Wee1-like protein kinase Human genes 0.000 claims 8
- 239000002246 antineoplastic agent Substances 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 5
- 230000037430 deletion Effects 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 108020004705 Codon Proteins 0.000 claims 3
- 230000037433 frameshift Effects 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004298P | 2014-05-29 | 2014-05-29 | |
| US62/004,298 | 2014-05-29 | ||
| PCT/US2015/032351 WO2015183776A1 (en) | 2014-05-29 | 2015-05-26 | Methods for treating cancer with a wee1 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019232432A Division JP2020073520A (ja) | 2014-05-29 | 2019-12-24 | Ｗｅｅ１阻害剤を用いた癌を処置する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017517520A JP2017517520A (ja) | 2017-06-29 |
| JP2017517520A5 true JP2017517520A5 (enExample) | 2018-06-28 |
Family
ID=54699632
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569847A Pending JP2017517520A (ja) | 2014-05-29 | 2015-05-26 | Ｗｅｅ１阻害剤を用いた癌を処置する方法 |
| JP2019232432A Pending JP2020073520A (ja) | 2014-05-29 | 2019-12-24 | Ｗｅｅ１阻害剤を用いた癌を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019232432A Pending JP2020073520A (ja) | 2014-05-29 | 2019-12-24 | Ｗｅｅ１阻害剤を用いた癌を処置する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20170095479A1 (enExample) |
| EP (1) | EP3148544A4 (enExample) |
| JP (2) | JP2017517520A (enExample) |
| WO (1) | WO2015183776A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015183776A1 (en) * | 2014-05-29 | 2015-12-03 | Merck Sharp & Dohme Corp. | Methods for treating cancer with a wee1 inhibitor |
| WO2019134070A1 (en) * | 2018-01-02 | 2019-07-11 | Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine | Panda as novel therapeutic |
| AU2019403486B2 (en) | 2018-12-20 | 2025-04-24 | Amgen Inc. | KIF18A inhibitors |
| CA3165472A1 (en) * | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
| WO2021211549A1 (en) * | 2020-04-14 | 2021-10-21 | Amgen Inc. | Kif18a inhibitors for treatment of neoplastic diseases |
| CN115698006B (zh) * | 2020-06-17 | 2024-03-29 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的吡唑并[3，4-d]嘧啶-3-酮衍生物 |
| AU2021296140A1 (en) * | 2020-06-24 | 2023-01-05 | Pmv Pharmaceuticals, Inc. | Companion diagnostic tool for mutant p53 reactivating compounds |
| MX2024002391A (es) | 2021-08-26 | 2024-06-03 | Volastra Therapeutics Inc | Inhibidores de indolina de kif18a. |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5129812B2 (ja) * | 2007-06-15 | 2013-01-30 | Ｍｓｄ株式会社 | ビシクロアニリン誘導体 |
| US20120157342A1 (en) * | 2009-09-02 | 2012-06-21 | Shinji Mizuarai | Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor |
| BR112013011918A2 (pt) * | 2010-11-16 | 2020-08-25 | Array Biopharma, Inc | inibidor de chk1, composição farmacêutica e kit compreendendo o referido inibidor |
| US9506926B2 (en) * | 2011-02-18 | 2016-11-29 | The Regents Of The University Of California | Molecular predictors of therapeutic response to specific anti-cancer agents |
| US9345705B2 (en) * | 2011-09-15 | 2016-05-24 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| WO2015183776A1 (en) * | 2014-05-29 | 2015-12-03 | Merck Sharp & Dohme Corp. | Methods for treating cancer with a wee1 inhibitor |
-
2015
- 2015-05-26 WO PCT/US2015/032351 patent/WO2015183776A1/en not_active Ceased
- 2015-05-26 EP EP15800163.6A patent/EP3148544A4/en not_active Ceased
- 2015-05-26 US US15/314,650 patent/US20170095479A1/en not_active Abandoned
- 2015-05-26 JP JP2016569847A patent/JP2017517520A/ja active Pending
-
2019
- 2019-12-06 US US16/705,592 patent/US11364243B2/en active Active
- 2019-12-24 JP JP2019232432A patent/JP2020073520A/ja active Pending
-
2022
- 2022-05-23 US US17/664,476 patent/US20230083689A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017517520A5 (enExample) | ||
| JP2016525097A5 (enExample) | ||
| PE20170312A1 (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso | |
| JP2015533176A5 (enExample) | ||
| JP2016533366A5 (enExample) | ||
| MX384828B (es) | Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. | |
| NZ602385A (en) | Methods of treating cancer | |
| MX2019001517A (es) | Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer. | |
| WO2015160975A3 (en) | Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer | |
| MX2018005071A (es) | Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp. | |
| EP3173092A3 (en) | Rna containing composition for treatment of tumor diseases | |
| MX2015011752A (es) | Metodos para tratar cancer de pulmon. | |
| PH12015502046B1 (en) | Pyridinyl and fused pyridinyl triazolone derivatives | |
| WO2015048689A8 (en) | Inhibitors of bruton's tyrosine kinase | |
| JP2015536950A5 (enExample) | ||
| PH12016502354A1 (en) | Pharmaceutical composition | |
| WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| MX2018004328A (es) | Composiciones farmaceuticas estabilizantes de camptotecina. | |
| JP2017528475A5 (enExample) | ||
| MX2017015936A (es) | Nueva composicion farmaceutica que comprende agentes tensioactivos no ionicos. | |
| PH12016502249B1 (en) | Pladienolide pyridine compounds and methods of use | |
| JP2015512398A5 (enExample) | ||
| MD20160016A2 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| WO2013112950A3 (en) | Certain chemical entities, compositions, and methods | |
| GB2538683A8 (en) | Irinotecan hydrochloride composite phospholipid composition preparation method and use thereof |